Related by context. All words. (Click for frequent words.) 65 Carotid Revascularization Endarterectomy vs. 64 multicenter randomized controlled 64 Refractory Angina 62 prospective randomized multicenter 62 phase IIIb 62 STRIDE PD 62 multicenter randomized clinical 61 Phase III multicenter 61 EVEREST II 61 MADIT II 61 Aggressive Reduction 61 multicenter prospective 61 ENESTnd 61 Enzastaurin 61 Randomized Clinical Trial 60 SPARCL 60 randomized Phase IIb 60 Delcath Phase III 60 Edge STudy 60 recurrent malignant glioma 60 ZACTIMA 60 Phase 2b kidney transplant 60 fosbretabulin 60 PFO migraine 60 ACCORD Lipid 60 placebo controlled clinical 60 CARE HF 60 number NCT# ClinicalTrials.gov 60 RE MODEL 59 Phase Ib clinical 59 thorough QT 59 Val HeFT 59 Asthma Intervention 59 PRoFESS 59 Rilonacept 59 Intervention Effectiveness 59 APEX PD 59 multicenter Phase II 59 MAGE A3 ASCI 59 NCIC CTG 59 cetrorelix pamoate 59 ADMIRE HF 59 Randomized Evaluation 59 prospective multicenter randomized 59 multicenter Phase III 59 ToGA 59 Fondaparinux 59 Pivotal Phase III 59 Dose Ranging Study 59 ONTARGET 59 Sipuleucel T 58 REALITY Trial 58 riociguat 58 randomized controlled multicenter 58 MIST II 58 fallopian tube cancers 58 blinded randomized placebo controlled 58 Multicenter 58 phase IIa clinical 58 Teriflunomide 58 prospective multicenter 58 Randomized controlled 58 RhuDex 58 CAMMS# 58 confirmatory clinical 58 Sirolimus eluting 58 Aflibercept 58 multicenter clinical 58 ADVANCE PD 58 Phase Ib II 58 INSPIRE Trial Phase III 58 TASKi3 58 Phase IIIb 58 ASTEROID 58 ZOLINZA 58 phase III isavuconazole 58 Safinamide 58 OvaRex MAb 57 neratinib 57 REMINYL ® 57 CHAMPION PCI 57 PROTECT AF 57 APEX AMI 57 Spine Patient Outcomes 57 Demonstrates Efficacy 57 Multicenter Automatic Defibrillator Implantation 57 CAPRIE 57 RE LY 57 Randomised 57 dose escalation phase 57 ECASS 57 placebo controlled multicenter 57 UPLYSO 57 Cholesterol Levels SPARCL 57 Antiarrhythmic 57 Prostate AdenoCarcinoma Treatment 57 ENDEAVOR IV 57 Daclizumab 57 BRIM2 57 Intervention Trial 57 FDA Approvals 57 multicentre randomized 57 AOD# [002] 57 pregabalin Lyrica 57 serotonin norepinephrine reuptake inhibitor 57 sorafenib Nexavar 57 Mycophenolate Mofetil 57 Hormone Refractory Prostate Cancer 57 Randomized Double blind 57 Eluting 57 implantable centrifugal rotary 57 Phase IIb III 56 Adenoma Prevention 56 Acute Myocardial Infarction 56 Investigational Treatment 56 VBLOC TM vagal blocking 56 Initiates Phase III 56 Combination REOLYSIN R 56 TASKi2 56 randomized multicentre 56 Meets Primary Endpoint 56 PERSEUS 56 Placebo controlled 56 TLK# 56 rosuvastatin Crestor 56 phase Ib 56 Randomized Phase II 56 blind multicenter 56 Phase 1b clinical trials 56 Glucosamine Chondroitin Arthritis 56 Bone Fracture 56 Bayer HealthCare Onyx Pharmaceuticals 56 Anticancer Drug 56 Initiated Phase 56 Phase 2b Clinical Trial 56 phase IIa 56 CLARITY TIMI 56 Pemetrexed 56 prospective randomized placebo 56 nonrandomized 56 EmbraceAC 56 randomized crossover 56 Severe Sepsis 56 Initiates Phase II 56 DIRECT Trial 56 reslizumab 56 Phase III randomized controlled 56 Long Term Efficacy 56 Cardiac Stem Cell 56 CALERIE 56 placebo controlled Phase 56 immunomodulatory agents 56 CHARM Added 56 treatment naive genotype 56 PREVENT IV 56 Cloretazine 56 Zarnestra 55 visilizumab 55 galiximab 55 National Emphysema Treatment 55 GW# [003] 55 AVERROES 55 Phase IIIb clinical 55 CaPSURE 55 receptor tyrosine kinase inhibitor 55 Recurrent Glioblastoma 55 Tarceva TM 55 Tyrima 55 multicentre prospective 55 CALGB # [002] 55 multicenter multinational 55 KRN# 55 DEB# 55 Pyridorin 55 prospective randomized controlled 55 Phase III psoriasis 55 MEND CABG 55 Sibutramine Cardiovascular Outcomes 55 icatibant 55 registrational Phase 55 HCV RESPOND 2 55 Randomized Controlled 55 Aliskiren 55 randomized multicenter 55 Left Ventricular Dysfunction 55 nab paclitaxel 55 biliary tract cancer 55 prospectively randomized 55 Glycopyrrolate 55 Fixed Dose 55 Secondary efficacy endpoints 55 PARTNER Trial 55 Advaxis Phase 55 Initiates Clinical Trial 55 relapsing multiple sclerosis 55 COSTAR II 55 Prostate Cancer Prevention 55 AIR CF1 55 prospective nonrandomized 55 Acne Drug 55 evaluating Actimmune 55 Completes Patient Enrollment 55 blinded placebo controlled 55 Phase III ThermoDox 55 Proellex TM 55 Raloxifene STAR 55 DEEP AF 55 Glaxo Tykerb 55 HDL Selective Delipidation 55 relapsed MM 55 HORIZONS AMI 55 ENDEAVOR III 55 multicenter placebo controlled 55 ACTIVE W 55 HCV SPRINT 55 IL# PE#QQR 55 CLARITY study 55 phase IIb clinical 55 Intervention Effectiveness CATIE 55 Glypromate 55 Phase #b/#a clinical 55 Aryplase 55 Teva Provides Update 55 TAXUS IV 55 keloid scarring 55 BRIM3 54 MEND CABG II 54 Phase III placebo controlled 54 Phase Ib IIa clinical 54 orally inhaled migraine 54 Slows Progression 54 recurrent glioblastoma multiforme 54 Transdermal Delivery 54 PRIMO CABG2 54 Initiates Enrollment 54 Antihypertensive 54 Phase IIB 54 Initiate Phase 54 MADIT 54 Ophena 54 Multiple Ascending Dose 54 multicentre randomized controlled 54 Phase Ib IIa 54 Enlarged Prostate 54 de novo kidney transplant 54 tramiprosate Alzhemed TM 54 EXPLORE Xa 54 Arranon 54 IND Application 54 Anturol TM 54 Pegylated Liposomal Doxorubicin 54 CALGB 54 MEVACOR 54 regorafenib 54 Pafuramidine 54 catheter occlusion 54 TMC# C# 54 oral rivaroxaban 54 randomized clinical 54 comparing XIENCE V 54 RCW breast cancer 54 Deforolimus 54 HOPE TOO 54 IMPACT DCM 54 ExTRACT TIMI 54 Prostate Lung Colorectal 54 Aplidin 54 weekly subcutaneous injections 54 Toremifene 54 RELOVAIR ™ 54 Atypical Antipsychotic 54 Androxal TM 54 BLOOM DM 54 Clinical Antipsychotic Trials 54 Dacogen decitabine 54 placebo controlled Phase III 54 teriflunomide 54 Pooled Analysis 54 BoNTA 54 Trandolapril 54 Ophena TM 54 phase III ACCLAIM 54 Platelet Inhibition 54 metastatic pancreatic 54 CIMZIA TM certolizumab pegol 54 Randomized Double Blind 54 Initiate Phase II 54 metastatic malignant 54 Node Positive 54 FDA Okays 54 + Perifosine Evaluation 54 Helps Smokers Quit 54 zoledronic acid Reclast 54 landmark ATHENA 54 investigational protease inhibitor 54 Kamada AAT 54 Prevent Stroke 53 Temsirolimus 53 eritoran 53 RIO Lipids 53 Dyloject TM 53 Liraglutide Effect 53 MGd 53 LHRH receptor positive 53 undergoing Percutaneous Coronary 53 abacavir Ziagen 53 interferon gamma 1b 53 EURIDIS 53 Fracture Intervention Trial 53 ILLUSTRATE 53 Xelox 53 double blinded randomized 53 olaparib 53 acyclovir Lauriad R 53 Bayer Onyx 53 polyarticular 53 FIRMAGON R 53 Zilver PTX Drug Eluting 53 VESTASYNC 53 GSK# [001] 53 thalidomide Thalomid 53 nucleotide analogue 53 Adjunctive 53 PF # [002] 53 Randomized Phase 53 randomized Phase III 53 lexidronam injection 53 cediranib 53 NSABP B 53 Patients Treated With 53 CVT E# 53 Phase 1b clinical 53 TG MV 53 Patients Receiving 53 CryoPlasty 53 multicenter randomized double 53 Migraine Treatment 53 VICTOR E3 53 Shows Promise Against 53 evaluating satraplatin plus 53 Phase III HEAT 53 Fluorouracil 53 Alequel 53 randomized multicenter trial 53 Vidaza azacitidine 53 Preclinical Study 53 Early Relapsing Multiple 53 NO# [002] 53 Metabolic Disorder 53 Stem Cells Used 53 hormone refractory metastatic prostate 53 Pharmacologic 53 Phase III VISTA 53 Pivotal Phase 53 ORAL Sync 53 topiramate Topamax 53 Heterozygous Familial Hypercholesterolemia 53 Matrix Phase 2b 53 PYY #-# 53 Cardiac Disease 53 Zoraxel 53 HIV HCV coinfected 53 Zemplar Capsules 53 palifermin 53 Immunosuppressant 53 Phase 1a clinical 53 blinded randomized 53 Targretin capsules 53 Carbamazepine 53 ongoing Phase 1b 53 Unstable Angina 53 Sprycel dasatinib 53 imexon 53 ropinirole Requip 53 phase IIb study 53 multicenter randomized 53 Lucanix 53 bortezomib Velcade 53 REVIVE Diabetes 53 cardiac repolarization 53 Pharmacodynamics 53 phase Ib clinical 53 asymptomatic hyperuricemia 53 IMPACT DCM clinical 53 randomized controlled clinical 53 humanised monoclonal antibody 53 phase IIb III 52 AVOREN 52 Celebrex celecoxib 52 pivotal bioequivalence 52 lapatinib Tykerb 52 vagus nerve stimulation VNS 52 Phase III Psoriasis 52 AVADO 52 SIMPADICO 52 Intravitreal 52 pretransplant 52 Therapy Improves 52 Darusentan 52 histamine dihydrochloride 52 placebo controlled dose escalation 52 Randomized placebo controlled 52 Adjuvant Treatment 52 tarenflurbil 52 balsalazide tablet 52 Platinol ® cisplatin 52 evaluating MGCD# [002] 52 ascending dose study 52 OvaRex ® MAb 52 Immunomodulatory 52 Corlux 52 PRIMO CABG 52 Bosutinib 52 Non Invasive Treatment 52 Ovidrel 52 mapatumumab 52 Dose Finding 52 Cancidas 52 randomized blinded 52 masked placebo controlled 52 Phase IIA 52 ALN VSP Phase 52 finasteride Proscar 52 recurrent metastatic 52 CA9 SCAN 52 anti arrhythmic drug 52 Oxybutynin 52 resectable pancreatic cancer 52 AIM HIGH 52 Paraplatin ® 52 Phase III ADT 52 placebo controlled randomized 52 Genentech Provides Update 52 TAXUS V 52 pravastatin Pravachol 52 Heel Pain 52 Drug Fails 52 somatostatin analog 52 Anti VEGF 52 SPIRIT FIRST 52 Almorexant 52 Trial Evaluating 52 Improves Outcomes 52 5 fluorouracil leucovorin 52 LymphoStat B TM 52 Clinical Efficacy 52 Appears Safe 52 Protease Inhibitor 52 cisplatin gemcitabine 52 EDEMA3 52 #I TM# 52 Neuvenge 52 VBLOC vagal blocking 52 ASSERT 52 pioglitazone hydrochloride 52 ROCKET AF 52 NeuroVax 52 multicenter Phase 52 Ropinirole 52 Protease Inhibitors 52 DSMB recommended 52 olmesartan 52 relapsed myeloma 52 Bevacizumab Avastin 52 pharmacokinetics PK 52 multicenter phase 52 ARBITER 6 52 multicenter randomized Phase 52 highly selective inhibitor 52 tipifarnib 52 NEVO RES 52 Estrogen Alone 52 ASCEND HF 52 roscovitine 52 CATIE AD 52 WHEL 52 mild hepatic impairment 52 Decompensated Heart Failure 52 Efficacy Trial 52 Glatiramer acetate 52 BR.# 52 Vertos II 52 Telithromycin 52 orBec 51 multicenter randomized placebo controlled 51 Pulminiq 51 CRLX# 51 Psoriasis Drug 51 Scandinavian Simvastatin Survival 51 PANVAC VF 51 blind randomized controlled 51 Diamyd r 51 Meridia sibutramine 51 Pimavanserin 51 evaluating mipomersen 51 pharmacodynamic effects 51 double blinded placebo 51 subanalysis 51 Phase III AFFIRM 51 trastuzumab Herceptin ® 51 Epilepsy Drug 51 Adrenomyeloneuropathy AMN 51 Platinol ® 51 Fulvestrant 51 Plaquenil 51 fluvastatin 51 CUSTOM II 51 randomized #:#:# 51 irinotecan oxaliplatin 51 Initiates Phase 2b 51 multicentric 51 PEGylated interferon beta 1a 51 chemotherapy cisplatin 51 aflibercept VEGF Trap 51 analgesic efficacy 51 lenalidomide Revlimid 51 canagliflozin 51 MKC# MT 51 Prolongs Life 51 phase IIb 51 GOUT 51 paricalcitol 51 ACCEDE 51 Atrial Flutter 51 sitagliptin Januvia 51 Idenix Novartis 51 cilostazol 51 RE LY trial 51 ENDEAVOR II 51 ABSORB trial 51 Temodar ® 51 Antiangiogenic 51 Eliquis 51 Reduce Cardiovascular 51 Subgroup analysis 51 Antidiabetic 51 huN# DM1 51 Sustained Efficacy 51 metreleptin 51 interferon beta 1b 51 modified REGENESIS Phase IIb 51 oral ridaforolimus 51 including cyclosporine methotrexate 51 pharmacokinetic PK study 51 signal detection CTSD 51 Hepatotoxicity 51 Mitomycin C 51 Launches Generic Version 51 Phase #b/#a 51 5 Fluorouracil 51 ELACYT 51 dose escalation clinical 51 Study Shows Benefits 51 GSK# [002] 51 BETAS 51 Progressive Multifocal Leukoencephalopathy 51 Dabigatran 51 Postmenopausal Osteoporosis 51 Lipid lowering 51 Raloxifene Evaluation MORE 51 DU #b 51 Genes Discovered 51 ritonavir boosted 51 Therapeutic Intervention 51 Excessive Sweating 51 Pharmacokinetics PK 51 basiliximab 51 Cocaine Addiction 51 Paxil paroxetine 51 Pharmacokinetic 51 RECORD1 51 mycophenolate mofetil 51 Ultrasound Imaging 51 Motexafin Gadolinium 51 ONCONASE R 51 Female Sexual Dysfunction 51 risperidone Risperdal 51 Vicriviroc 51 Vidaza ® 51 Levels Linked 51 Resten MP 51 hypoxia activated prodrug 51 Placebo Controlled 51 irbesartan 51 Bisphosphonate 51 AVAiL 51 alvespimycin 51 targeted antifolate 51 Exemestane 51 Zybrestat 51 rhIGF-I/rhIGFBP-3 51 Phase III confirmatory 51 Pagoclone 51 retinal vein occlusion induced 51 epoetin alpha 51 PROSTVAC VF 51 active comparator 51 AstraZeneca Targacept 51 XL# SAR# 51 unfractionated heparin UFH 51 Velcade bortezomib 51 IIa trials 50 Vertex hepatitis C 50 Intravenous immunoglobulin 50 cromolyn sodium 50 multicentre randomized double 50 Antitumor 50 OMP #R# 50 TAXUS ATLAS 50 Capesaris 50 beta 1a 50 assessing T DM1 50 pertuzumab 50 Escitalopram 50 Multicenter Randomized 50 randomized controlled 50 Active Ulcerative Colitis 50 orally administered inhibitor 50 alefacept 50 Generic Phentermine 50 occlusion PAO 50 lymphomas leukemias 50 WHIMS 50 Physician Insights 50 Romidepsin 50 Long Lesion 50 Femara letrozole 50 Suppositories 50 PREVU x Point 50 controlled multicenter Phase 50 blood clot dissolving 50 Hormone Replacement 50 injectable diclofenac 50 phase 2a 50 INS# [001] 50 Breast Implant 50 BOLDER II 50 daily Infergen 50 beta carotene supplementation 50 randomized multicenter Phase III 50 papillary renal cell carcinoma 50 COPEGUS R 50 Relapsing Multiple Sclerosis 50 demonstrated antitumor activity 50 selective phosphodiesterase 50 randomized placebo controlled 50 visit http:/www.clinicaltrials.gov/ 50 Anticonvulsant 50 zonisamide SR 50 citalopram Celexa 50 Differential Diagnosis 50 vaccine Stimuvax 50 CEL SCI Phase III 50 BRAF inhibitor 50 VNP#M 50 Neural Therapy 50 Randomized 50 nccam.nih.gov 50 ziprasidone Geodon 50 undergoing hematopoietic stem 50 mg administered orally 50 SORT OUT III 50 Generalised Anxiety Disorder 50 CINQUIL 50 everolimus eluting 50 selenium supplementation 50 Watchful Waiting 50 alendronate Fosamax 50 briakinumab 50 antidepressants fluoxetine 50 preclinical efficacy 50 Prednisone Against Refractory 50 COU AA 50 midstage clinical 50 Pressure Monitoring 50 Levetiracetam 50 Panzem R NCD 50 imetelstat GRN#L 50 hoFH 50 Refractory Hodgkin Lymphoma 50 opioid naive 50 Predict Response 50 Treating Depression 50 steroid refractory 50 AKT inhibitor 50 Vorapaxar 50 Diagnostic Criteria 50 compound INCB# 50 Antidepressant Drug 50 SPRYCEL ® 50 tenofovir Viread 50 Myocardial Infarction Study 50 AIR CF2 50 blind randomized placebo 50 azilsartan medoxomil 50 TRITON TIMI 50 noninvasive outpatient 50 Pegylated Interferon 50 TransVax tm 50 Irritable Bowel 50 rALLy 50 Combo Therapy 50 Uterine Fibroids 50 pramlintide metreleptin combination 50 heFH 50 Vidaza R 50 Omnitarg 50 Treatment Reduces 50 reversing heparin 50 multidose 50 Cloretazine ® 50 Triapine 50 EEG abnormalities 50 Omacetaxine 50 Tykerb lapatinib 50 Doxil ® 50 phosphodiesterase inhibitors 50 Maximum Tolerated Dose MTD 50 VIVUS Announces 50 Obtains CE Mark 49 HYVET 49 Gonal f 49 Control Unit MFCU 49 PROTECT II 49 Picoplatin Efficacy After 49 investigational antiplatelet agent 49 BZA CE 49 ACCOMPLISH 49 RhuDex TM 49 Dr. Montori 49 candidates Dyloject TM 49 #mg dosing 49 SPRIX ® 49 Nonsurgical 49 noscapine 49 TransMID 49 stage IIIb IV 49 gamma secretase inhibitor 49 Latuda 49 CHMP Opinion 49 Multivessel Evaluation 49 Prolonged Exposure 49 immunocompetent adults 49 pyrimidine nucleoside analog 49 Panzem NCD 49 refractory colorectal cancer 49 percutaneous catheter 49 minimally invasive implantable 49 Hyalgan 49 drug NP2 Enkephalin 49 Analytical Tool 49 Phase #b/#a trial 49 pharmacokinetic characteristics 49 Preclinical Models 49 Complicated Skin 49 ABSORB clinical 49 Intraocular 49 evaluating Vectibix 49 Reduces Pain 49 MVax R 49 Injectable Fillers 49 subcutaneous methylnaltrexone 49 HF ACTION 49 Natazia 49 Atherosclerotic 49 Phase 1b trial 49 maximally tolerated dose 49 Neuromuscular Disorders 49 hyaluronidase enzyme 49 Extracorporeal Shock Wave 49 ReCharge 49 rufinamide 49 Sleep Disturbances 49 Cinquil 49 autoimmune uveitis 49 Triapine R 49 senicapoc 49 postmenopausal hormone replacement 49 Ziprasidone 49 velafermin 49 Parathyroid Hormone 49 Serada 49 dose escalation Phase 49 FDA defined valvulopathy 49 Forodesine HCl 49 glycoprotein IIb IIIa inhibitor 49 interferon alpha IFN alpha 49 metastatic castration resistant 49 metaanalysis 49 canakinumab 49 paclitaxel Taxol R 49 mg subcutaneous 49 Ferinject R 49 Neuroprotective 49 QLT# 49 Further Validates 49 neurologic progression 49 Neo Bladder Augment 49 relapsed ALL 49 estramustine 49 GRNOPC1 contains 49 TransVax 49 pharmacodynamics PD 49 OMP #M# 49 Ortho Dermatologics 49 Hospital Acquired Pneumonia 49 Heavy Menstrual Bleeding 49 Motility 49 hepatic insufficiency 49 conjugated estrogen 49 alpha 2a 49 Calmare pain 49 Chronic Pelvic Pain 49 Phase #/#a 49 Phase IIb kidney transplant 49 OAB overactive bladder 49 WX UK1 49 levodopa induced dyskinesia 49 Retinal Vein Occlusion 49 anastrazole 49 enoxaparin Lovenox 49 Polyp Prevention Trial 49 initiate Phase IIa 49 metronidazole gel 48 Histopathological 48 mycophenolate mofetil MMF 48 pentostatin 48 specified primary endpoint 48 preclinical pharmacokinetic 48 Degenerative Disc Disease 48 gemcitabine carboplatin 48 adjuvant colon cancer 48 Pain Medication 48 OvaRex 48 Cellulite Treatment 48 everolimus eluting stents 48 Study Raises Questions 48 dalteparin 48 lamotrigine Lamictal 48 Chronic Cerebrospinal Venous Insufficiency 48 Causes Symptoms 48 fenretinide 48 Migraine Headache 48 Help Smokers Quit 48 Cloretazine R 48 evaluating tivozanib 48 Remergent 48 volumetric modulated arc 48 atypical hemolytic uremic syndrome 48 Emtriva Viread 48 G CSFs 48 Posaconazole 48 intravenous RSD# 48 Imatinib mesylate 48 genotypic resistance 48 Opioid Dependence 48 Corticosteroid 48 ISTODAX ® 48 stage chemoresistant ovarian 48 evaluating satraplatin 48 EINSTEIN DVT 48 Conor CoStar 48 COR Diabetes 48 PPAR gamma agonist 48 POISE 48 Lifewatch 48 GetGoal Phase III 48 advanced medullary thyroid 48 please visit www.abraxane.com 48 antiretroviral naïve 48 Anacetrapib 48 Gemzar gemcitabine 48 relapsed ovarian cancer 48 blind randomized 48 Myelodysplastic Syndrome MDS 48 Serevent salmeterol 48 undergoing peritoneal dialysis 48 #:#-#,# CrossRef Medline [002] 48 injectable urethral bulking 48 CLIRS 48 rheumatoid arthritis osteoarthritis ankylosing 48 Trigeminal Neuralgia 48 ISAR TEST 48 Generic Propecia 48 taxane resistant 48 Investigational Oral 48 fistulizing Crohn disease 48 MVA MUC1 IL2 48 Bipolar Mania 48 randomized Phase 2b 48 Pharmacokinetic studies 48 headache nasopharyngitis 48 #mg ATC 48 refractory myeloma 48 Fluvastatin 48 venlafaxine XR 48 Am J Manag 48 Cancer AACR NCI 48 ralfinamide 48 Bcr Abl inhibitors 48 Lowers Blood Pressure 48 Vectical 48 subcutaneous SC 48 Phototherapy 48 systemic RNAi therapeutic 48 BenzaClin R 48 Kinoid 48 LCP Tacro 48 Oral Insulin Capsule 48 Pain Therapy 48 evaluating Xcytrin 48 VICTOR E1 48 Lofexidine 48 Phase lll 48 pramipexole Mirapex 48 cutaneous lymphoma 48 Cloretazine R VNP#M 48 TQT 48 Anti Wrinkle 48 abacavir lamivudine 48 3TC lamivudine Epivir 48 Provacel 48 Chemoprevention 48 Phase IIb IIIa 48 Vaccine Shows Promise 48 #:#-#,# CrossRef Medline [001] 48 Stronger Warnings 48 ascending dose 48 daily subcutaneous injections 48 miglustat 48 prostate cancer HRPC 48 GRNVAC1 47 FOLFOX6 chemotherapy regimen 47 Lipitor #mg 47 sublingual tablets 47 treat premature ejaculation 47 TomoMobile ™ relocatable radiation 47 refractory HL 47 Skin Resurfacing 47 placebo controlled 47 underwent liver transplantation 47 dose atorvastatin 47 VEGF inhibitor 47 Cellular Immunotherapy 47 Presents Preclinical Data 47 lowering triglyceride levels 47 Acne Scars 47 conducted retrospective cohort 47 clomipramine 47 Shown Effective 47 Often Misdiagnosed 47 de novo coronary 47 Vincristine 47 #:#-#,# [002] 47 Bioequivalence 47 MIRAPEX ER 47 initiated Phase Ib 47 induce remission 47 efavirenz EFV 47 SPEAR Study 47 convulsive disorders 47 lumiliximab 47 Tension Headache 47 TTF Therapy 47 intravenous cyclophosphamide 47 LAB CGRP 47 OVATURE 47 aurora kinase inhibitor 47 Substance Dependence 47 Temodar temozolomide 47 tolevamer 47 Chemotherapy Induced 47 eosinophilic asthma 47 PreSAP 47 FDA Approves Generic 47 #mg/#mg 47 Pemphigus 47 iii GTx 47 Immunosuppressive 47 PEGINTRON REBETOL combination 47 Ereska 47 #:#-#,# Medline 47 flutamide 47 journal Lancet Neurology 47 basal insulin analogue 47 ® lenalidomide 47 dimebon latrepirdine 47 blinded randomized controlled 47 Leukocyte 47 trastuzumab DM1 47 FDA Warns Against 47 Dermal Fillers 47 visceral metastases 47 Gilead Viread 47 uridine triacetate 47 Urine Test 47 Eases Pain 47 Phase Ia 47 Diet Supplement